Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CURTAXEL: Curcumin + Taxotere in mCRPC
NCT02095717Phase 2Terminated
- Sponsor
- Centre Jean Perrin
- Start
- Mar 2014
- Primary completion
- Apr 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Curcumin Arm with Placebo Arm (2 arms). Primary endpoint: Time to Progression. Started Mar 2014; status: terminated.
02
Drugs
curcumin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02095717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02095717.